Innate Pharma SA Business Summary

Innate Pharma SA (IPHA) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, research funding, and milestone payments from global pharmaceutical partners, including AstraZeneca, Sanofi, and Bristol-Myers Squibb. The company operates through two core business segments: its proprietary ANKET (Antibody-based NK cell Engager Therapeutics) platform, which develops multi-specific natural killer (NK) cell engagers, and its antibody-drug conjugate (ADC) portfolio targeting solid tumors. Its lead clinical assets include lacutamab, currently in Phase 3 trials for cutaneous T-cell lymphoma, and monalizumab, a checkpoint inhibitor partnered with AstraZeneca. Innate Pharma competes directly with oncology-focused biotechs such as Affimed, Agenus, and Arcus Biosciences, as well as large-cap players like Merck. Within this landscape, Innate positions itself as a specialized pioneer in NK cell biology, leveraging its deep expertise in the innate immune system to serve as a high-value R&D engine for larger pharmaceutical collaborators. Founded in 1999 by a scientific team including Hervé Brailly, Eric Vivier, Marc Bonneville, and Jean-Jacques Fournié, the company is currently led by Chief Executive Officer Jonathan Dickinson, who joined in late 2024 following senior leadership roles at Incyte, ARIAD, and Roche. The executive team is further bolstered by Chief Operating Officer Yannis Morel, who oversees research and early development, and Chief Medical Officer Sonia Quaratino, a veteran of Novartis and Merck Serono. Financial operations are managed by CFO Frédéric Lombard, formerly of Intercell and AstraZeneca. The company’s governance is overseen by Board Chairwoman Irina Staatz-Granzer and includes notable directors such as Christian Itin (CEO of Autolus) and Olivier Martinez, representing Bpifrance. Significant institutional backing is provided by Bpifrance and Orbimed, alongside equity-linked strategic partnerships with major industry stakeholders.